Your browser is no longer supported. Please, upgrade your browser.
Applied Genetic Technologies Corporation
Index- P/E- EPS (ttm)-2.26 Insider Own0.66% Shs Outstand42.75M Perf Week-0.26%
Market Cap158.30M Forward P/E- EPS next Y-1.70 Insider Trans0.00% Shs Float36.27M Perf Month-3.96%
Income-56.50M PEG- EPS next Q-0.41 Inst Own53.00% Short Float14.83% Perf Quarter-37.22%
Sales0.00M P/S- EPS this Y9.70% Inst Trans45.04% Short Ratio2.18 Perf Half Y-25.24%
Book/sh1.60 P/B2.43 EPS next Y11.70% ROA-62.30% Target Price- Perf Year-9.13%
Cash/sh1.30 P/C2.98 EPS next 5Y- ROE-89.20% 52W Range3.53 - 9.67 Perf YTD-5.13%
Dividend- P/FCF- EPS past 5Y-7.80% ROI-58.30% 52W High-59.88% Beta2.21
Dividend %- Quick Ratio3.90 Sales past 5Y0.80% Gross Margin- 52W Low9.92% ATR0.29
Employees83 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)44.43 Volatility7.08% 7.29%
OptionableYes Debt/Eq0.24 EPS Q/Q-26.20% Profit Margin- Rel Volume0.40 Prev Close3.67
ShortableYes LT Debt/Eq0.24 EarningsFeb 11 BMO Payout- Avg Volume2.47M Price3.88
Recom1.70 SMA20-2.03% SMA50-15.65% SMA200-21.85% Volume983,212 Change5.72%
Mar-02-21Initiated Stifel Buy $14
Feb-02-21Reiterated H.C. Wainwright Buy $18 → $24
Nov-11-20Initiated Berenberg Buy
Jun-23-20Initiated Cantor Fitzgerald Overweight $14
Jan-28-20Initiated ROTH Capital Buy
Jan-27-20Initiated ROTH Capital Buy
Sep-27-19Upgrade BMO Capital Markets Market Perform → Outperform $5 → $9
Sep-27-19Reiterated H.C. Wainwright Buy $12 → $18
Sep-06-19Initiated Janney Buy $13
Sep-14-17Reiterated Stifel Buy $15 → $12
May-11-17Reiterated Stifel Buy $18 → $15
Mar-15-17Initiated Rodman & Renshaw Buy $16
Nov-09-16Upgrade ROTH Capital Neutral → Buy
Nov-09-16Reiterated Wedbush Outperform $20 → $17
Sep-13-16Reiterated Wedbush Outperform $36 → $20
Sep-13-16Reiterated Stifel Buy $29 → $24
Sep-13-16Downgrade Wells Fargo Outperform → Market Perform
Sep-13-16Downgrade ROTH Capital Buy → Neutral
Sep-13-16Downgrade Cantor Fitzgerald Buy → Hold
Feb-09-16Reiterated Stifel Buy $32 → $29
May-14-21 12:54PM  
May-13-21 04:03PM  
May-11-21 04:05PM  
May-06-21 09:04AM  
May-05-21 04:05PM  
May-04-21 08:00AM  
May-03-21 08:39AM  
Apr-29-21 07:30AM  
Apr-28-21 07:30AM  
Apr-26-21 04:02PM  
Apr-19-21 07:00AM  
Apr-13-21 07:00AM  
Mar-31-21 08:00AM  
Mar-25-21 07:00AM  
Mar-18-21 12:00PM  
Mar-02-21 07:00AM  
Feb-16-21 12:00PM  
Feb-11-21 07:00AM  
Feb-04-21 12:03PM  
Jan-28-21 08:07AM  
Jan-27-21 04:35PM  
Jan-24-21 11:26PM  
Jan-06-21 04:01PM  
Dec-11-20 03:05PM  
Dec-10-20 11:33PM  
Dec-01-20 11:35AM  
Nov-16-20 05:35PM  
Nov-11-20 07:00AM  
Nov-10-20 04:05PM  
Oct-27-20 06:29AM  
Oct-21-20 07:00AM  
Oct-08-20 07:00AM  
Oct-07-20 07:00AM  
Sep-12-20 09:20AM  
Sep-09-20 07:00AM  
Sep-03-20 04:05PM  
Sep-02-20 04:05PM  
Aug-25-20 07:00AM  
Aug-12-20 07:00AM  
Aug-04-20 07:00AM  
Jul-22-20 07:00AM  
Jul-14-20 06:47AM  
Jul-07-20 09:11PM  
Jun-26-20 12:00PM  
Jun-24-20 08:40AM  
Jun-23-20 04:05PM  
Jun-22-20 07:00AM  
Jun-16-20 04:01PM  
Jun-15-20 07:00AM  
Jun-10-20 11:30AM  
May-26-20 10:50AM  
May-25-20 12:00PM  
May-20-20 07:00AM  
May-15-20 06:24AM  
May-13-20 10:45AM  
May-12-20 08:00AM  
May-06-20 07:00AM  
Apr-28-20 12:34PM  
Apr-22-20 07:20AM  
Mar-24-20 12:00PM  
Mar-16-20 07:00AM  
Feb-19-20 07:00AM  
Feb-16-20 08:50AM  
Feb-06-20 08:06PM  
Feb-05-20 04:36PM  
Jan-28-20 07:30AM  
Jan-23-20 07:00AM  
Jan-22-20 04:01PM  
Jan-21-20 07:00AM  
Jan-10-20 10:08AM  
Jan-09-20 10:02AM  
Jan-08-20 04:01PM  
Dec-19-19 09:17AM  
Dec-17-19 07:36PM  
Dec-04-19 08:19PM  
Dec-03-19 07:59AM  
Dec-02-19 04:35PM  
Nov-12-19 05:55PM  
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.